Compounds > 3,6-dioxa-1,8-octanedithiol
Page last updated: 2024-12-07

3,6-dioxa-1,8-octanedithiol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,6-dioxa-1,8-octanedithiol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID84733
CHEMBL ID3187655
SCHEMBL ID58951
MeSH IDM0445684

Synonyms (54)

Synonym
LS-13222
NCIOPEN2_001476
ethanethiol,2'-[1,2-ethanediylbis(oxy)]bis-
2,2'-(ethylenedioxy)diethanethiol
ethanethiol,2'-(ethylenedioxy)di-
nsc94782
1,2-bis(2-mercaptoethoxy)ethane
14970-87-7
triethyleneglycol dimercaptan
nsc-94782
triglycol dimercaptan
2,2'-(ethylenedioxy)diethanethiol, 95%
ethylene glycol bis(2-mercaptoethyl) ether
3,6-dioxa-1,8-octanedithiol
1,8-dimercapto-3,6-dioxaoctane
D2649
2-[2-(2-sulfanylethoxy)ethoxy]ethanethiol
ethanethiol, 2,2'-(1,2-ethanediylbis(oxy))bis-
einecs 239-044-2
nsc 94782
2,2'-(1,2-ethanediylbis(oxy))bis(ethanethiol)
triethylene glycol dimercaptan
83ca1m23nc ,
unii-83ca1m23nc
ethanethiol, 2,2'-(ethylenedioxy)di-
cas-14970-87-7
2,2'-[ethane-1,2-diylbis(oxy)]diethanethiol
NCGC00255902-01
dtxcid7024588
dtxsid9044588 ,
tox21_301482
3,6-dioxa-1,8-octane-dithiol
BP-30005
FT-0614769
2-[2-(2-sulfanylethoxy)ethoxy]ethane-1-thiol
ethanethiol, 2,2'-[1,2-ethanediylbis(oxy)]bis-
AKOS015913916
2,2'-(ethane-1,2-diylbis(oxy))diethanethiol
2,2-(ethylenedioxy)diethanethiol
2,2'-(1,2-ethanediylbis(oxy))bisethanethiol
3,6-dioxaoctane-1,8-dithiol [mi]
dodt
SCHEMBL58951
W-110400
2,2'-[1,2-ethanediyl-bis(oxy)]bis(ethanethiol)
CHEMBL3187655
mfcd00015873
HCZMHWVFVZAHCR-UHFFFAOYSA-N
AMY9433
AT13664
2,2'-(ethane-1,2-diylbis(oxy))bis(ethane-1-thiol)
Q27269426
EN300-7399543
sh-peg2-sh
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency76.95880.000714.592883.7951AID1259368
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency64.86010.001022.650876.6163AID1224838; AID1224893
retinoid X nuclear receptor alphaHomo sapiens (human)Potency21.68460.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency6.68110.001530.607315,848.9004AID1224848; AID1224849; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency4.85580.005428.02631,258.9301AID1346982
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency27.53570.023723.228263.5986AID743223
Histone H2A.xCricetulus griseus (Chinese hamster)Potency126.79300.039147.5451146.8240AID1224845
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency15.96760.000627.21521,122.0200AID743202; AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's6 (75.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.51 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
valproic acid
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.		3.2710branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
ethylenediamine
ethylenediamine: RN given refers to parent cpd; edamine is the recommended contraction for the ethylenediamine radical. ethylenediamine : An alkane-alpha,omega-diamine in which the alkane is ethane.		2.0610alkane-alpha,omega-diamineGABA agonist
alanine
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.		2.0210alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
trifluoroacetic acid
Trifluoroacetic Acid: A very strong halogenated derivative of acetic acid. It is used in acid catalyzed reactions, especially those where an ester is cleaved in peptide synthesis.. trifluoroacetic acid : A monocarboxylic acid that is the trifluoro derivative of acetic acid.		2.0210fluoroalkanoic acidhuman xenobiotic metabolite;
NMR chemical shift reference compound;
reagent
triethylamine
[no description available]		2.0710tertiary amine
dithiothreitol
1,4-dimercaptobutane-2,3-diol : A glycol that is butane-2,3-diol in which a hydrogen from each of the methyl groups is replaced by a thiol group.. 1,4-dithiothreitol : The threo-diastereomer of 1,4-dimercaptobutane-2,3-diol.		2.07101,4-dimercaptobutane-2,3-diol;
butanediols;
dithiol;
glycol;
thiol		chelator;
human metabolite;
reducing agent
platinum
Platinum: A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as alutiae.		7.0710elemental platinum;
nickel group element atom;
platinum group metal atom
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		2.06101,2,3-triazole
folic acid
folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.		3.2710folic acids;
N-acyl-amino acid		human metabolite;
mouse metabolite;
nutrient
ConditionIndicatedRelationship StrengthStudiesTrials
Pregnancy in Diabetes
[description not available]		03.0910
Diabetes Mellitus, Gestational
[description not available]		03.0910
Abnormalities, Drug-Induced
Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.		03.0910
Delayed Effects, Prenatal Exposure
[description not available]		03.0910
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		03.0910
Diabetes, Gestational
Diabetes mellitus induced by PREGNANCY but resolved at the end of pregnancy. It does not include previously diagnosed diabetics who become pregnant (PREGNANCY IN DIABETICS). Gestational diabetes usually develops in late pregnancy when insulin antagonistic hormones peaks leading to INSULIN RESISTANCE; GLUCOSE INTOLERANCE; and HYPERGLYCEMIA.		03.0910